SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. All participants will receive FHD-286 orally once daily in 21-day cycles. The primary objective is to assess the objective response rate of FHD-286 in this population. The names of the study drug involved in this study is: • FHD-286 (a small-molecule SMARCA4/2 ATPase (BRG1 and BRM) inhibitor targeting the SWI/SNF chromatin remodeling complex (also known as the BAF complex)
Sponsor: Dana-Farber Cancer Institute
You may qualify if…
- ✓ Adult age l8 years or older, who have provided written informed consent.
- ✓ Histologically or cytologically confirmed extensive stage SCLC with documented disease progression or recurrence after prior platinum-based therapy with or without checkpoint inhibitor.
- ✓ Positive \>50% POU2F3 expression by IHC staining.
- ✓ Participants must have measurable disease based on RECIST v1.1.
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or l.
- ✓ Participants must meet the following organ and marrow function criteria:
- ✓ leukocytes ≥2,000/mcL
- ✓ absolute neutrophil count (ANC) ≥1,000/mcL
You may not qualify if…
- ✕ Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia.
- ✕ Participants who are receiving any investigational therapy
- ✕ Symptomatic brain metastases (untreated, asymptomatic brain metastases are eligible if size \<6 mm).
- ✕ Participants receiving any medications or substances that are strong inhibitors, strong inducers, or sensitive CYP3A substrates (with narrow therapeutic indices) of CYP3A enzymes are ineligible (see also Section 3.3).
- ✕ Individuals must have stopped treatment with strong CYP3A inhibitors at least 1 week or 5 half-lives, whichever is longer, before the first dose of study drug. Strong CYP3A inhibitors may be permitted with PI approval; the FHD-286 dose should be reduced to 1.5 mg QD when a strong CYP3A inhibitor is in use.
- ✕ Individuals must have stopped treatment with strong CYP3A inducers at least 2 weeks or 5 half-lives, whichever is longer, before the first dose of study drug. Strong CYP3A inducers may be permitted with PI approval.
- ✕ Stable doses of immunosuppressants that are sensitive CYP3A substrates with narrow therapeutic indices may be permitted with PI approval.
- ✕ Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
Where it's recruiting
Boston
Source: ClinicalTrials.gov · NCT07551635 · last updated 2026-10-26